Istituto Clinico Humanitas
androgen deprivation therapy (ADT)(Istituto Clinico Humanitas)은 Oligorecurrent and Oligoprogressive Pros 표적 치료제로, Oligorecurrent and Oligoprogressive Prostate Cancer Patients 영역에서 개발·상용화 중입니다. 작용기전: targeting Vβ6 and Vβ10 T-cell receptor. 전임상 단계입니다. PFS: 0. 차별점: Novel Flavone-Sulfonamide Hybrid Derivatives as Potential Anticancer Agents.
Oligorecurrent and Oligoprogressive Pros
Oligorecurrent and Oligoprogressive Prostate Cancer Patients
Recruiting
Novel Flavone-Sulfonamide Hybrid Derivatives as Potential Anticancer Agents
targeting Vβ6 and Vβ10 T-cell receptor
T-cell activation
biomarker-driven studies in larger cohorts to refine treatment strategies
resistance to androgen deprivation therapy (ADT), presenting a substantial therapeutic challenge
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Istituto Clinico Humanitas
androgen deprivation therapy (ADT)(Istituto Clinico Humanitas)은 Oligorecurrent and Oligoprogressive Pros 표적 치료제로, Oligorecurrent and Oligoprogressive Prostate Cancer Patients 영역에서 개발·상용화 중입니다. 작용기전: targeting Vβ6 and Vβ10 T-cell receptor. 전임상 단계입니다. PFS: 0. 차별점: Novel Flavone-Sulfonamide Hybrid Derivatives as Potential Anticancer Agents.
Oligorecurrent and Oligoprogressive Pros
Oligorecurrent and Oligoprogressive Prostate Cancer Patients
Recruiting
Novel Flavone-Sulfonamide Hybrid Derivatives as Potential Anticancer Agents
targeting Vβ6 and Vβ10 T-cell receptor
T-cell activation
biomarker-driven studies in larger cohorts to refine treatment strategies
resistance to androgen deprivation therapy (ADT), presenting a substantial therapeutic challenge
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.